Philip J Saylor1, R Bryan Rumble2, Scott Tagawa3, James A Eastham4, Antonio Finelli5, Pavan S Reddy6, Terry M Kungel7, Merel G Nissenberg8, Jeff M Michalski9. 1. Massachusetts General Hospital, Boston, MA. 2. American Society of Clinical Oncology, Alexandria, VA. 3. Weill Cornell Medicine, New York, NY. 4. Memorial Sloan Kettering Cancer Center, New York, NY. 5. Princess Margaret Cancer Center, University Health Network, and University of Toronto, Toronto, Ontario, Canada. 6. Cancer Center of Kansas, Wichita, KS. 7. Patient Representative, Woolwich, ME. 8. Patient Representative, Los Angeles, CA. 9. Washington University School of Medicine, St Louis, MO.
Abstract
PURPOSE: In 2017, Cancer Care Ontario's Program in Evidence-Based Care released the Bone Health and Bone-Targeted Therapies for Prostate Cancer guideline. This guideline included recommendations across a relatively broad clinical spectrum within prostate cancer. Topics addressed ranged from management of osteoporotic fracture risk in nonmetastatic disease to management of men with castration-resistant prostate cancer metastatic to bone. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. METHODS: The Bone Health and Bone-Targeted Therapies for Prostate Cancer guideline was reviewed for developmental rigor by methodologists. An ASCO Expert Panel then reviewed the content and the recommendations. RESULTS: The ASCO Expert Panel determined that the recommendations from the Bone Health and Bone-Targeted Therapies for Prostate Cancer guideline were clear, thorough, and based on the most relevant scientific evidence. ASCO wholly endorses the Bone Health and Bone-Targeted Therapies for Prostate Cancer guideline. RECOMMENDATIONS: The ASCO Expert Panel endorses all the original guideline recommendations as written and offers a series of discussion points to guide practice for clinicians as they manage bone-related risks within this patient population.
PURPOSE: In 2017, Cancer Care Ontario's Program in Evidence-Based Care released the Bone Health and Bone-Targeted Therapies for Prostate Cancer guideline. This guideline included recommendations across a relatively broad clinical spectrum within prostate cancer. Topics addressed ranged from management of osteoporotic fracture risk in nonmetastatic disease to management of men with castration-resistant prostate cancer metastatic to bone. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. METHODS: The Bone Health and Bone-Targeted Therapies for Prostate Cancer guideline was reviewed for developmental rigor by methodologists. An ASCO Expert Panel then reviewed the content and the recommendations. RESULTS: The ASCO Expert Panel determined that the recommendations from the Bone Health and Bone-Targeted Therapies for Prostate Cancer guideline were clear, thorough, and based on the most relevant scientific evidence. ASCO wholly endorses the Bone Health and Bone-Targeted Therapies for Prostate Cancer guideline. RECOMMENDATIONS: The ASCO Expert Panel endorses all the original guideline recommendations as written and offers a series of discussion points to guide practice for clinicians as they manage bone-related risks within this patient population.
Authors: Samuel U Takvorian; Vrushabh P Ladage; E Paul Wileyto; Drew S Mace; Rinad S Beidas; Lawrence N Shulman; Justin E Bekelman Journal: JAMA Oncol Date: 2020-07-01 Impact factor: 31.777
Authors: Lisa Marie Ruppert; Erica Dayan Cohn; Niamh M Keegan; Abigail Bacharach; Sungmin Woo; Theresa Gillis; Howard I Scher Journal: JCO Oncol Pract Date: 2022-02-17
Authors: Janet E Brown; Catherine Handforth; Juliet E Compston; William Cross; Nigel Parr; Peter Selby; Steven Wood; Lawrence Drudge-Coates; Jennifer S Walsh; Caroline Mitchell; Fiona J Collinson; Robert E Coleman; Nicholas James; Roger Francis; David M Reid; Eugene McCloskey Journal: J Bone Oncol Date: 2020-08-02 Impact factor: 4.072
Authors: Kefeng Liu; Yanfang Ma; Yongjie Yang; Jingli Lu; Jie Zhao; Shuzhang Du; Xuepei Zhang; Chunlei Liu; Francesco Del Giudice; Masaki Shiota; Shingo Hatakeyama; Xiaojian Zhang; Jian Kang Journal: Ann Transl Med Date: 2021-07
Authors: Benoit Cadieux; Robert Coleman; Pegah Jafarinasabian; Allan Lipton; Robert Z Orlowski; Fred Saad; Giorgio V Scagliotti; Kazuyuki Shimizu; Alison Stopeck Journal: J Bone Oncol Date: 2022-02-07 Impact factor: 4.072
Authors: J E Brown; S L Wood; C Confavreux; M Abe; K Weilbaecher; P Hadji; R W Johnson; J A Rhoades; C M Edwards; P I Croucher; P Juarez; S El Badri; G Ariaspinilla; S D'Oronzo; T A Guise; C Van Poznak Journal: J Bone Oncol Date: 2021-06-11 Impact factor: 4.072